APA (7th ed.) Citation

Tatar, M., Kaplan, B., Arbay, D., & Akdemir, A. (2024). EE119 Cost Effectiveness of Asciminib for the Post 2 Tyrosine Kinase Inhibitor Treatment of Chronic Phase Chronic Myeloid Leukaemia in Türkiye. Value in Health, 27(12), S77. https://doi.org/10.1016/j.jval.2024.10.403

Chicago Style (17th ed.) Citation

Tatar, M., B. Kaplan, D. Arbay, and AC Akdemir. "EE119 Cost Effectiveness of Asciminib for the Post 2 Tyrosine Kinase Inhibitor Treatment of Chronic Phase Chronic Myeloid Leukaemia in Türkiye." Value in Health 27, no. 12 (2024): S77. https://doi.org/10.1016/j.jval.2024.10.403.

MLA (9th ed.) Citation

Tatar, M., et al. "EE119 Cost Effectiveness of Asciminib for the Post 2 Tyrosine Kinase Inhibitor Treatment of Chronic Phase Chronic Myeloid Leukaemia in Türkiye." Value in Health, vol. 27, no. 12, 2024, p. S77, https://doi.org/10.1016/j.jval.2024.10.403.